for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

Last week­end, re­searchers gath­ered in San Diego for the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing to dis­cuss the lat­est ad­vance­ments and clin­i­cal tri­ ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

The White Lotus Fame Aimee Lou Wood Calls Gap In Her Smile 'Symbol Of Rebellion': But There's A Limit... Actress Aimee Lou Wood feels "sad" when her teeth get more attention than her acting work. The ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the drug would ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis. Amgen’s anti-CD19 antibody Uplizna ...

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein telitacicept in patients with generalized myasthenia gravis, offering a ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...